1 min read|55 words
Long-term data from Nature Medicine's NI006-101 trial show cliramitug—a monoclonal antibody against misfolded transthyretin—sustains clinical benefit in cardiac amyloidosis over 29.3 months, with reduced amyloid burden and improved heart function. This represents a major shift from supportive care to disease-directed therapy in rare genetic cardiomyopathy.
Read the full article on GMJ Newsroom →
Was this article helpful?
